www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/1984

Title: Analysis of oxaliplatin reintroduction in patients with advanced colorectal cancer (CRC) treated with FOLFOX4 or FOLFOX7 in the optimox study
Authors: BUYSE, Marc
Quinaux, E
CORTINAS ABRAHANTES, Jose
Tournigand, C
Cervantes, A
Figer, A
André, Thierry
Tabah-Fisch, I
De Gramont, A
Issue Date: 2006
Publisher: OXFORD UNIV PRESS
Citation: ANNALS OF ONCOLOGY, 17. p. 115-115
Abstract: Background: In the OPTIMOX1 study, previously untreated patients, (pts) with advanced CRC were randomized to either FOLFOX4 every 2 wks until progressio (arm A), or FOLFOX7 (arm B). There was no difference between arms in response rate, progression-free survival, and overall survival (OS)[Tournigand, JCO 2006;24:394]. The effect of oxaliplatin reintroduction on survival was inconclusive as a significant number of pts received oxaliplatin in both arms after being taken off the study. This retrospective analysis evaluated the effect of oxaliplatin reintroduction on OS. Methods: The % of pts with oxaliplatin reintroducion was calculated in each center regardless of treatment arm, number of pts, or whether reintroduction was per protocol. A Cox model was used to analyze impact of oxaliplatin reintroduction on survival, after adjustment for all baseline covariates, and using random effects to account for the fact that % pts with oxilaplatin reintroduction was estimated in each center. Centers were grouped into 4 reintroduction classes according to o% pts with oxaliplatin reintroduction (0, 1–20, 21–40, and >40). The hazard ratio (HR; adjusted for all baseline covariates) was calculated for each reintroduction class. Results: After adjustment for all other factors,% pts with oxaliplatin reintroduction had a highly significant impact on survival (p<0.001). Reintroduction class also had a significant impact on survival, after adjustment for all other factors (p=0.02; Table below). Median survival increased from 15 months in the 0% to 23 months in the >40% reintroduction class.
Notes: Int Inst Drug Dev, Brussels, Belgium. Hasselt Univ, Ctr Stat, Hasselt, Belgium. Hop St Antoine, Med Oncol Serv, F-75571 Paris, France. Univ Hosp Valencia, Valencia, Spain. Elias Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel. Hop Tenon, Med Oncol Serv, F-75970 Paris, France. Sanofi Aventis, Paris, France.
URI: http://hdl.handle.net/1942/1984
ISI #: 000248078900340
ISSN: 0923-7534
Category: M
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.